Clinical Trials

Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease (ParkFit)

Radboud University
Parkinson's Disease (PD)
physical activity
Patients with Parkinson's disease (PD) are heavily inclined towards a sedentary lifestyle. This is caused by a combination of physical impairments and cognitive dysfunction. However, regular Responses: 0 ... 

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease

Clinical & Biological Features
Schering-Plough
Early Parkinson's Disease
Drug
preladenant
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist. The purpose of Part 1 (first 26 weeks) is to determine if Responses: 1 ... 

A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease

Parkinson's Disease (PD)
Drug
nebicapone
This is a study to determine the efficacy, safety, and tolerability of nebicapone, a COMT inhibitor, to treat PD. Responses: 0 ... 

Controlled Trial on the Effect of 10 Days Low-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) on Motor Signs in Parkinson's Disease

Parkinson's Disease (PD)
rTMS
Low-frequency rTMS was investigated for its effect on motor signs in PD. The authors conclude that the protocol has no therapeutic value. Responses: 0 ... 

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease

Therapeutic Development
Cephalon
Parkinson's Disease (PD)
Drug
CEP-1347
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease. Responses: 0 ... 

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With PD Requiring Initiation of Levodopa Therapy (STRIDE-PD)

Novartis
Parkinson's Disease
Drug
carbidopa/levodopa/entacapone
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in Responses: 0 ... 

A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease

Therapeutic Development
gene therapy
This Phase I study examined the safety, tolerability and possible efficacy of gene delivery of aromatic L-amino acid decarboxylase (AADC), mediated by an adeno-associated virus vector. The gene was Responses: 0 ... 

Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone

Clinical Features, Pharmacological Approaches
University of Medicine and Dentistry New Jersey
Parkinson's Disease Insomina
Drug
Eszopiclone
Parkinson's disease (PD) is the second most common neurodegenerative disease in the US, affecting nearly 1 million Americans. Up to 82% of community dwelling individuals with PD complain of Responses: 0 ... 

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy

Promoting Neurotrophic Processes
Eisai Inc.
Parkinson's Disease
Drug
GPI 1485
This study was designed to assess whether GPI 1485 has the ability to delay or stop disease progression and improve symptoms in patients with Parkinson's disease (PD) that is already being Responses: 0 ... 

Sarizotan in the Treatment of Neuroleptic-Induced Tardive Dyskinesia

Dopamine-Based Approaches, Dyskinesia, Cognitive Symptoms, Serotonin-Based Approaches
Centre for Addiction and Mental Health
Neuroleptic-Induced Tardive Dyskinesia
Drug
Sarizotan
TD is a troublesome and potentially irreversible side effect associated with the use of neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry the Responses: 0 ...